Consider condition in step therapy
THE BEST STEP therapy programs first consider medical evidence regarding patient outcomes when identifying drug classes for inclusion, according to industry experts.
THE BEST STEP therapy programs first consider medical evidence regarding patient outcomes when identifying drug classes for inclusion, according to industry experts.
"The strongest candidates are typically medications that are clearly second line to other drugs based on national clinical guidelines or good practices," says Edmund Pezalla, MD, MPH, vice president, medical director, Prescription Solutions. "In classes where good generic alternatives exist, branded products also are common to these programs."
Antidiabetic medications can be considered for step therapy. "With several newer agents on the market and at a fairly high cost compared with generic metformin and/or sulfonylureas, there is an opportunity to establish first-line and second-line agents," he explains.
HIV drugs and drugs used in cancer chemotherapy are classes of drugs that also might be appropriate for step therapy, adds Rogers.
STEP INTO THE FUTURE
As new generics become available in key classes and "me-too" drugs are introduced into a market where cheaper alternatives exist, there will be more opportunity for step therapy programs to have a financial impact, Dr. Pezalla believes. "Increasingly, managed care organizations and others will rely upon these programs to keep pace with pharmaceutical product releases in order to deliver the best clinical and financial outcomes. This will make it even more important that the programs are based on national guidelines and good practice."
Ultimately, step therapy will allow easier access to medications for members who meet guidelines, decrease impact to operations and reduce cost. "As more information becomes available to the claims system, data integration will make step therapy and prior authorization smarter processes, incorporating diagnosis as well as utilization into the logic," Dr. Pezalla says.
-Tracey WalkerCommentary is independent of source data
David Calabrese of OptumRx Talks New Role, Market Insulin Prices and Other Topics 'On His Mind'
April 13th 2023In this month’s episode of the "What's On Your Mind podcast," Peter Wehrwein, managing editor of MHE connects with the now Chief Clinical Officer of OptumRx Integrated Pharmacies, David Calabrese. In this conversation, David touches on his transition in January as OptumRx’s former chief pharmacy officer and market president of health plans and PBMs to his new role as Chief Clinical Officer where he now focuses more on things such as specialty pharmacy to home delivery — with an overall goal of creating whole-patient care. Throughout the conversation, Calabrese also touched on the market’s hot topic of insulin prices and behavioral health services within the OptumRx community, among other topics.
Listen
Upended: Can PBM Transparency Succeed?
March 6th 2024Simmering tensions in the pharmacy benefit management (PBM) industry have turned into fault lines. The PBMs challenging the "big three" have formed a trade association. Purchaser coalitions want change. The head of the industry's trade group says inherent marketplace friction has spilled over into political friction.
Read More
Briana Contreras, editor of Managed Healthcare Executive, spoke with Nancy Lurker, CEO and president of EyePoint Pharmaceuticals. Nancy shared a bit about EyePoint and how the organization’s innovative therapies are addressing patient needs through eye care, and most importantly, she addressed C-Suite positions like the CEO role. Nancy shared advice for those seeking to reach the CEO level, especially toward women in healthcare and other roles, and what it takes to run a biopharma company.
Listen
The deliberate disconnection of Change Healthcare to ring fence a cyberattack entered its seventh day today. Prescribers are finding ways to get pharmacy claims processed, and UnitedHealth Group says disruption to the dispensing of prescriptions has been minimal. But independent pharmacies want more information and protection from financial consequences from pharmacy benefit managers.
Read More
